Therapeutic modalities continue to advance for the benefit of our patients, and in the meantime, exhibits complexity from molecular structures and chemical and biological processes. Hence, the analysis of multicomponent and multiphase pharmaceutical systems in natural abundance increasingly challenge the resolution and sensitivity of the spectroscopic techniques used.
Solid-state Nuclear Magnetic Resonance (ssNMR) spectroscopy is a powerful tool that can precisely characterize the structure and dynamics of complex molecules and materials. The past decade has witnessed significant technical advancements in the field of ssNMR for overcoming the challenges of low sensitivity and poor resolution, such as dynamic nuclear polarization (DNP), proton-detected spectroscopy, ultrafast magic angle spinning (UF MAS) and the development of multi-nuclear and multi-dimensional methods. These advances have opened new avenues for ssNMR in application to emerging modalities in the pharmaceutical industry, especially for understanding liposomal and liquid crystal formulations, lipid nanoparticles, amorphous dispersions and lyophilized biologic products. ssNMR techniques can obtain structural, dynamic and spatial information at macroscopic and microscopic scales, offering critical knowledge to help understand and optimize drug delivery, chemical and physical stability, bioavailability, formulation composition, and manufacturing processes for simple small molecule formulation to complex modalities and drug delivery systems.
Thursday July 15, 2021
Yongchao Su, Ph.D
Principal Scientist and Head of Biopharmaceutical NMR Laboratory (BNL) in Pharmaceutical Sciences at Merck & Co, Inc.
Associate Scientific Director, ssNMR Team Lead
Bristol Myers Squibb
Principal Scientist Genentech
Senior Scientist Janssen Pharmaceutical NV